Publikasi Scopus 926 artikel (Per 14 Maret 2022)

Doxorubicin (DOX) has been widely used in the clinical setting for malignancy treatment.However, it also induces toxicity in a vital organ such as the kidney. Several studies suggest theformation of an iron anthracycline complex which produces free radicals plays an important role innephrotoxicity.Mangiferin (MGF), a xanthone derivate, exhibits as an iron chelator and antioxidant activitythrough a free radical scavenger activity. We analyzed the effect of MGF to prevent DOX inducednephrotoxicity. Male Sprague-Dawley rats were administered MGF orally every day for five weeks,with 50 and 100 mg/kg BW together with DOX. Renal failure and dyslipidemia were detected in theDOX groups in association with increased malondialdehyde (MDA) levels in plasma and kidney anddecreased superoxide dismutase (SOD) and glutathione (GSH) levels in kidney. Of note, cotreatmentwith MGF improved renal dysfunction caused by doxorubicin as shown by theamelioration plasma albumin, urea and creatinine levels, and proteinuria. MGF also diminishedover-production of MDA levels, thus enhanced antioxidant activity such as SOD and GSH in thekidney.Our study opens the perspective to clinical studies for consideration of MGF as a potentialchemoprotectant nutraceutical in the combination chemotherapy with DOX to limit its nephrotoxicity © 2021, Journal of International Dental and Medical Research. All Rights Reserved.